JP5844358B2

JP5844358B2 - ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤

ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 Download PDF

Info

Publication number: JP5844358B2
Authority: JP; Japan
Prior art keywords: alkyl; methyl; chlorophenyl; triazolo; ethylacetamide
Prior art date: 2010-06-22
Legal status : Expired - Fee Related

Application number

JP2013515827A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013529611A5 (enExample

JP2013529611A (ja

Inventor

バイリー，ジェームズ，マシュー

Original Assignee

グラクソスミスクラインエルエルシー

Priority date

2010-06-22

Filing date

2011-06-20

Publication date

2016-01-13

2010-06-22 Priority claimed from GBGB1010514.6A external-priority patent/GB201010514D0/en

2011-04-21 Priority claimed from GBGB1106801.2A external-priority patent/GB201106801D0/en

2011-06-20 Application filed by グラクソスミスクラインエルエルシー, グラクソスミスクラインエルエルシー filed Critical グラクソスミスクラインエルエルシー

2013-07-22 Publication of JP2013529611A publication Critical patent/JP2013529611A/ja

2014-06-05 Publication of JP2013529611A5 publication Critical patent/JP2013529611A5/ja

2016-01-13 Application granted granted Critical

2016-01-13 Publication of JP5844358B2 publication Critical patent/JP5844358B2/ja

Status Expired - Fee Related legal-status Critical Current

2031-06-20 Anticipated expiration legal-status Critical

Links

102000001805 Bromodomains Human genes 0.000 title description 49
108050009021 Bromodomains Proteins 0.000 title description 48
239000003112 inhibitor Substances 0.000 title description 18
WTJDTOLWJBAXRX-UHFFFAOYSA-N triazolo[4,5-g][1,2]benzodiazepine Chemical class C1=CC2=NN=CC=CC2=C2C1=NN=N2 WTJDTOLWJBAXRX-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 151
125000000217 alkyl group Chemical group 0.000 claims description 91
150000003839 salts Chemical class 0.000 claims description 89
-1 —CO-carbocyclyl Chemical group 0.000 claims description 53
125000000623 heterocyclic group Chemical group 0.000 claims description 32
239000001257 hydrogen Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
125000005843 halogen group Chemical group 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 26
125000003545 alkoxy group Chemical group 0.000 claims description 25
125000004452 carbocyclyl group Chemical group 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 17
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
150000002431 hydrogen Chemical class 0.000 claims description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 11
125000005842 heteroatom Chemical group 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
229910052717 sulfur Inorganic materials 0.000 claims description 10
125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
201000011510 cancer Diseases 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
230000004968 inflammatory condition Effects 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 6
230000001684 chronic effect Effects 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
QKKNSYUKNJSTRL-NDEPHWFRSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-[3-(pyrrolidin-1-ylmethyl)phenyl]-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=C(CN3CCCC3)C=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 QKKNSYUKNJSTRL-NDEPHWFRSA-N 0.000 claims description 5
UCHHERPHYGYXQM-NDEPHWFRSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-[4-(pyrrolidin-1-ylmethyl)phenyl]-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC(CN3CCCC3)=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 UCHHERPHYGYXQM-NDEPHWFRSA-N 0.000 claims description 5
230000001363 autoimmune Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000004193 piperazinyl group Chemical group 0.000 claims description 5
125000003386 piperidinyl group Chemical group 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
PJPRMRNFJZOFLA-FQEVSTJZSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(1h-pyrazol-4-yl)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C2=CNN=C2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 PJPRMRNFJZOFLA-FQEVSTJZSA-N 0.000 claims description 4
WMKQEPQCESYBNS-FQEVSTJZSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(1h-pyrazol-5-yl)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2NN=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 WMKQEPQCESYBNS-FQEVSTJZSA-N 0.000 claims description 4
HFCOQWDWESZNEW-DEOSSOPVSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(2-methylphenyl)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C(=CC=CC=2)C)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 HFCOQWDWESZNEW-DEOSSOPVSA-N 0.000 claims description 4
PILKZSVRGDSFDN-LJAQVGFWSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=C(CN3CCN(C)CC3)C=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 PILKZSVRGDSFDN-LJAQVGFWSA-N 0.000 claims description 4
DODSTUSXECRXBY-LJAQVGFWSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC(CN3CCN(C)CC3)=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 DODSTUSXECRXBY-LJAQVGFWSA-N 0.000 claims description 4
LBNZQYJSQFKTMP-QHCPKHFHSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 LBNZQYJSQFKTMP-QHCPKHFHSA-N 0.000 claims description 4
MXNRKTOXHIEBKM-QFIPXVFZSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-pyridin-4-yl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CN=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 MXNRKTOXHIEBKM-QFIPXVFZSA-N 0.000 claims description 4
SPAMVIHCDISFJZ-DEOSSOPVSA-N 2-[(4s)-6-(4-chlorophenyl)-8-(3-methoxyphenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=C(OC)C=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 SPAMVIHCDISFJZ-DEOSSOPVSA-N 0.000 claims description 4
DBNRUVQIPZTZFK-DEOSSOPVSA-N 2-[(4s)-6-(4-chlorophenyl)-8-(4-methoxyphenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC(OC)=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 DBNRUVQIPZTZFK-DEOSSOPVSA-N 0.000 claims description 4
JZVFVHUUEWVBPO-SANMLTNESA-N 2-[(4s)-6-(4-chlorophenyl)-8-[3-(ethylaminomethyl)phenyl]-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound CCNCC1=CC=CC(C=2C=C3C(N4C(C)=NN=C4[C@H](CC(=O)NCC)N=C3C=3C=CC(Cl)=CC=3)=CC=2)=C1 JZVFVHUUEWVBPO-SANMLTNESA-N 0.000 claims description 4
PHVGVVDKYSSPKA-SANMLTNESA-N 2-[(4s)-6-(4-chlorophenyl)-8-[4-(ethylaminomethyl)phenyl]-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound C1=CC(CNCC)=CC=C1C1=CC=C2N3C(C)=NN=C3[C@H](CC(=O)NCC)N=C(C=3C=CC(Cl)=CC=3)C2=C1 PHVGVVDKYSSPKA-SANMLTNESA-N 0.000 claims description 4
USCJQEZHNLJYPQ-SANMLTNESA-N 2-[(4s)-6-(4-chlorophenyl)-8-[4-[(dimethylamino)methyl]phenyl]-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC(CN(C)C)=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 USCJQEZHNLJYPQ-SANMLTNESA-N 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
230000005784 autoimmunity Effects 0.000 claims description 3
229940049706 benzodiazepine Drugs 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
125000002757 morpholinyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
150000001557 benzodiazepines Chemical class 0.000 claims 1
KYTREVLPRJOBEM-UHFFFAOYSA-N triazolo[4,5-i][1,2]benzodiazepine Chemical group C1=CC2=CC=CN=NC2=C2C1=NN=N2 KYTREVLPRJOBEM-UHFFFAOYSA-N 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
235000002639 sodium chloride Nutrition 0.000 description 85
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 69
239000011541 reaction mixture Substances 0.000 description 62
239000000203 mixture Substances 0.000 description 59
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 53
239000000243 solution Substances 0.000 description 49
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 43
239000002904 solvent Substances 0.000 description 42
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 34
235000019253 formic acid Nutrition 0.000 description 34
239000007787 solid Substances 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
239000000543 intermediate Substances 0.000 description 33
238000002360 preparation method Methods 0.000 description 32
238000000034 method Methods 0.000 description 30
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
239000012044 organic layer Substances 0.000 description 27
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
201000010099 disease Diseases 0.000 description 19
235000019439 ethyl acetate Nutrition 0.000 description 19
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 17
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
238000001819 mass spectrum Methods 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
229910052796 boron Inorganic materials 0.000 description 15
239000000843 powder Substances 0.000 description 15
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
108010033040 Histones Proteins 0.000 description 13
229960000583 acetic acid Drugs 0.000 description 13
239000010410 layer Substances 0.000 description 13
229940125763 bromodomain inhibitor Drugs 0.000 description 12
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
235000011054 acetic acid Nutrition 0.000 description 11
239000012267 brine Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
239000002158 endotoxin Substances 0.000 description 11
239000003921 oil Substances 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
239000000725 suspension Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 10
239000012530 fluid Substances 0.000 description 10
229920006008 lipopolysaccharide Polymers 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
238000012360 testing method Methods 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000003556 assay Methods 0.000 description 9
238000009472 formulation Methods 0.000 description 9
239000012299 nitrogen atmosphere Substances 0.000 description 9
239000011734 sodium Substances 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
UXRDAJMOOGEIAQ-CKOZHMEPSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UXRDAJMOOGEIAQ-CKOZHMEPSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
239000002585 base Substances 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
238000000746 purification Methods 0.000 description 8
229910000029 sodium carbonate Inorganic materials 0.000 description 8
USGDSUYKHJTOBN-KRWDZBQOSA-N [(4s)-6-(4-chlorophenyl)-4-[2-(ethylamino)-2-oxoethyl]-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-8-yl] trifluoromethanesulfonate Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 USGDSUYKHJTOBN-KRWDZBQOSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
239000002027 dichloromethane extract Substances 0.000 description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
239000000047 product Substances 0.000 description 7
239000012321 sodium triacetoxyborohydride Substances 0.000 description 7
239000012453 solvate Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
UXTPELVEOZWSPO-DEOSSOPVSA-N 2-[(4s)-6-(4-chlorophenyl)-8-(4-formylphenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=CC(C=O)=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 UXTPELVEOZWSPO-DEOSSOPVSA-N 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
102000006947 Histones Human genes 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 6
210000003483 chromatin Anatomy 0.000 description 6
229940079593 drug Drugs 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000003446 ligand Substances 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
RYZOXPQDWCYWSH-DEOSSOPVSA-N 2-[(4s)-6-(4-chlorophenyl)-8-(3-formylphenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=C(C=O)C=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 RYZOXPQDWCYWSH-DEOSSOPVSA-N 0.000 description 5
102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 5
108010077544 Chromatin Proteins 0.000 description 5
101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
GXPYEYLUXCAMOH-UHFFFAOYSA-N O=S(C(F)(F)F)(OC(C=C1)=CC2=C1C=NC=CN2)=O Chemical compound O=S(C(F)(F)F)(OC(C=C1)=CC2=C1C=NC=CN2)=O GXPYEYLUXCAMOH-UHFFFAOYSA-N 0.000 description 5
206010040047 Sepsis Diseases 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000006071 cream Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 5
238000000198 fluorescence anisotropy Methods 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
238000011200 topical administration Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
WROWJIQIIZGGJK-KRWDZBQOSA-N 2-[(4s)-6-(4-chlorophenyl)-8-hydroxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(O)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 WROWJIQIIZGGJK-KRWDZBQOSA-N 0.000 description 4
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
108091005625 BRD4 Proteins 0.000 description 4
102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 4
102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
206010033645 Pancreatitis Diseases 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000001973 epigenetic effect Effects 0.000 description 4
238000011049 filling Methods 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000003380 propellant Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
239000007921 spray Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
OJTKTQWQGFWAJM-KRWDZBQOSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(2h-tetrazol-5-yl)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C2=NNN=N2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 OJTKTQWQGFWAJM-KRWDZBQOSA-N 0.000 description 3
UXZBZRYYPOQUAG-SFHVURJKSA-N 2-[(4s)-6-(4-chlorophenyl)-8-cyano-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C#N)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 UXZBZRYYPOQUAG-SFHVURJKSA-N 0.000 description 3
VEIZLTSJCDOIBH-INIZCTEOSA-N 2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid Chemical compound C=1C(OC)=CC=C(N2C(C)=NN=C2[C@H](CC(O)=O)N=2)C=1C=2C1=CC=C(Cl)C=C1 VEIZLTSJCDOIBH-INIZCTEOSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
208000037487 Endotoxemia Diseases 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
239000007821 HATU Substances 0.000 description 3
208000007514 Herpes zoster Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
208000010718 Multiple Organ Failure Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
108010047956 Nucleosomes Proteins 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
206010047115 Vasculitis Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
229940009098 aspartate Drugs 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
238000012054 celltiter-glo Methods 0.000 description 3
150000001793 charged compounds Chemical class 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000006184 cosolvent Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
RNIAZRFBVXSBEM-KRWDZBQOSA-N ethyl 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(trifluoromethylsulfonyloxy)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C11)CC(=O)OCC)=C1C1=CC=C(Cl)C=C1 RNIAZRFBVXSBEM-KRWDZBQOSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000006260 foam Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
OXOGNSKOSOXORL-INIZCTEOSA-N methyl 2-[(3s)-5-(4-chlorophenyl)-7-methoxy-2-sulfanylidene-1,3-dihydro-1,4-benzodiazepin-3-yl]acetate Chemical compound N([C@H](C(NC1=CC=C(OC)C=C11)=S)CC(=O)OC)=C1C1=CC=C(Cl)C=C1 OXOGNSKOSOXORL-INIZCTEOSA-N 0.000 description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000001623 nucleosome Anatomy 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
238000000825 ultraviolet detection Methods 0.000 description 3
239000001993 wax Substances 0.000 description 3
MIQUXYBYLZSOIJ-UHFFFAOYSA-N (2-amino-5-methoxyphenyl)-(4-chlorophenyl)methanone Chemical compound COC1=CC=C(N)C(C(=O)C=2C=CC(Cl)=CC=2)=C1 MIQUXYBYLZSOIJ-UHFFFAOYSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
BCWQJVWEQGQZAR-NRFANRHFSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid Chemical compound N([C@@H](CC(O)=O)C1=NN=C(N1C1=CC=C(C=C11)C=2C=CC=CC=2)C)=C1C1=CC=C(Cl)C=C1 BCWQJVWEQGQZAR-NRFANRHFSA-N 0.000 description 2
IMUKVGUCKLGAAW-UHFFFAOYSA-N 6-methoxy-2-methyl-3,1-benzoxazin-4-one Chemical compound N1=C(C)OC(=O)C2=CC(OC)=CC=C21 IMUKVGUCKLGAAW-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
102100039869 Histone H2B type F-S Human genes 0.000 description 2
101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
206010033647 Pancreatitis acute Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
102000002689 Toll-like receptor Human genes 0.000 description 2
108020000411 Toll-like receptor Proteins 0.000 description 2
XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
206010069351 acute lung injury Diseases 0.000 description 2
201000003229 acute pancreatitis Diseases 0.000 description 2
239000004479 aerosol dispenser Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
125000000068 chlorophenyl group Chemical group 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
VCHMPRYCQXCAOR-KRWDZBQOSA-N ethyl 2-[(4s)-6-(4-chlorophenyl)-8-hydroxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(O)C=C11)CC(=O)OCC)=C1C1=CC=C(Cl)C=C1 VCHMPRYCQXCAOR-KRWDZBQOSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
RXFQKJSMQSBJLZ-INIZCTEOSA-N methyl 2-[(3s)-5-(4-chlorophenyl)-7-methoxy-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]acetate Chemical compound N([C@H](C(NC1=CC=C(OC)C=C11)=O)CC(=O)OC)=C1C1=CC=C(Cl)C=C1 RXFQKJSMQSBJLZ-INIZCTEOSA-N 0.000 description 2
FCJDMCOJXLHSKW-KRWDZBQOSA-N methyl 2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)OC)=C1C1=CC=C(Cl)C=C1 FCJDMCOJXLHSKW-KRWDZBQOSA-N 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
QDMVBBPBEVWLGW-BOXHHOBZSA-N n-(5-aminopentyl)-2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C(OC)=CC=C(N2C(C)=NN=C2[C@H](CC(=O)NCCCCCN)N=2)C=1C=2C1=CC=C(Cl)C=C1 QDMVBBPBEVWLGW-BOXHHOBZSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
201000008383 nephritis Diseases 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
230000007420 reactivation Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000009491 slugging Methods 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000002411 thermogravimetry Methods 0.000 description 2
125000005505 thiomorpholino group Chemical group 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 2
238000004704 ultra performance liquid chromatography Methods 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
239000003643 water by type Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
KOMRHPHTMKCPCD-UHFFFAOYSA-N 1,2-dimethoxyethanol Chemical group COCC(O)OC KOMRHPHTMKCPCD-UHFFFAOYSA-N 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
KEZNMOUMHOZFRA-UHFFFAOYSA-N 1h-pyrazol-4-ylboronic acid Chemical compound OB(O)C=1C=NNC=1 KEZNMOUMHOZFRA-UHFFFAOYSA-N 0.000 description 1
NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 1
UMKSAURFQFUULT-UHFFFAOYSA-N 2-Amino-5-methoxybenzoic acid Chemical compound COC1=CC=C(N)C(C(O)=O)=C1 UMKSAURFQFUULT-UHFFFAOYSA-N 0.000 description 1
AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 1
AFMIMJGSTNNGJW-QFIPXVFZSA-N 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-pyridin-3-yl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(C=C11)C=2C=NC=CC=2)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AFMIMJGSTNNGJW-QFIPXVFZSA-N 0.000 description 1
YRBQVPLXZMRHLA-UHFFFAOYSA-N 2-[4-methyl-3-oxo-7-(1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound N1C(CC(O)=O)C(=O)N(C)CC2=CC(C(=O)N3CC4=C(C5=CC=CC=C5N4)CC3)=CC=C21 YRBQVPLXZMRHLA-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
241000701386 African swine fever virus Species 0.000 description 1
239000012103 Alexa Fluor 488 Substances 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
YSWJWHTZYLBEDQ-KRWDZBQOSA-N CCNC(C[C@@H]1N=C(C(CC2)=CC=C2Cl)c(cc(cc2)O)c2-[n]2c1nnc2C)=O Chemical compound CCNC(C[C@@H]1N=C(C(CC2)=CC=C2Cl)c(cc(cc2)O)c2-[n]2c1nnc2C)=O YSWJWHTZYLBEDQ-KRWDZBQOSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
CDEMHJCJMMOFMB-UHFFFAOYSA-M ClC1=CC=C([Mg]Br)C=C1 Chemical compound ClC1=CC=C([Mg]Br)C=C1 CDEMHJCJMMOFMB-UHFFFAOYSA-M 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010061172 Gastrointestinal injury Diseases 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000013875 Heart injury Diseases 0.000 description 1
208000004898 Herpes Labialis Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
206010023125 Jarisch-Herxheimer reaction Diseases 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
208000009608 Papillomavirus Infections Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000005585 Poxviridae Infections Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
238000001237 Raman spectrum Methods 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
239000003875 Wang resin Substances 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
108091005646 acetylated proteins Proteins 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
238000003705 background correction Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000009787 cardiac fibrosis Effects 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
201000003740 cowpox Diseases 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000006195 histone acetylation Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
208000011379 keloid formation Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
229940050176 methyl chloride Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000000955 peptide mass fingerprinting Methods 0.000 description 1
239000002304 perfume Substances 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
239000000565 sealant Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000011493 spray foam Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
230000010741 sumoylation Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
WNNBEWZTXVXUTA-DEOSSOPVSA-N tert-butyl n-[5-[[2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetyl]amino]pentyl]carbamate Chemical compound C=1C(OC)=CC=C(N2C(C)=NN=C2[C@H](CC(=O)NCCCCCNC(=O)OC(C)(C)C)N=2)C=1C=2C1=CC=C(Cl)C=C1 WNNBEWZTXVXUTA-DEOSSOPVSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000002381 testicular Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
125000002769 thiazolinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000005029 transcription elongation Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
238000001665 trituration Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
238000013389 whole blood assay Methods 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000008096 xylene Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1